would not the upcoming (?) ASIAN/dndn corp partnership add additional value to DB analysis...... What about dndn's exclusive platform's application to other types of cancer besides prostate cancer......
An Asian partnership could happen any time, and would certainly add significant value to the current pps, as well as analyst targets.
The application of this technology to other cancers is some time off. DNDN needs to first enter, then complete phased trials, for each cancer and then submit the results to the FDA.
News announcements along the way ought to give us a strong clue as to where this will benefit DNDN, but I'd guess, purely from a layman's point of view, that the technology hinges on turning an individual's own immune system to attacking the cancer. Without any medical training, it sounds like a slam dunk but we need to complete the tests to be sure.
If it works this way (the tests will tell us if this is the case) then why can't this technology be employed for other medical conditions (not cancer) affected by a lowered immune system? The first thing that comes to mind is Aides, and that is only from my understanding of news reports.
The possibilities for DNDN are staggering. Perhaps that is why so many entities seen to be against this little company succeeding. And that would explain why DNDN is taking things one step at a time.
Time will tell. I'm holding for the very long term.